Terms: = Leukemia AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b AND Treatment
221 results:
1. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368
[TBL] [Abstract] [Full Text] [Related]
2. The novel TERF2::pdgfrb fusion gene enhances tumorigenesis via pdgfrb/STAT5 signalling pathways and sensitivity to TKI in ph-like ALL.
Xu GF; Zeng Z; Zhang ZB; Zhang XM; Wang M; Xiao Q; Li J; Xie XQ; He S; Fu HH; Liu Y; Yang ZL; Chen Y; Shi J; Wang B; Qiu HY; Zhou Q; Liu Y; Chen SN
J Cell Mol Med; 2024 Feb; 28(3):e18114. PubMed ID: 38323741
[TBL] [Abstract] [Full Text] [Related]
3. Identification of a Selective FLT3 Inhibitor with Low Activity against VEGFR, FGFR, pdgfr, c-KIT, and RET Anti-Targets.
Akwata D; Kempen AL; Dayal N; Brauer NR; Sintim HO
ChemMedChem; 2024 Jan; 19(1):e202300442. PubMed ID: 37971283
[TBL] [Abstract] [Full Text] [Related]
4. Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma.
De Coninck S; De Smedt R; Lintermans B; Reunes L; Kosasih HJ; Reekmans A; Brown LM; Van Roy N; Palhais B; Roels J; Van der Linden M; Van Dorpe J; Ntziachristos P; Van Delft FW; Mansour MR; Pieters T; Lammens T; De Moerloose B; De Bock CE; Goossens S; Van Vlierberghe P
Haematologica; 2024 May; 109(5):1373-1384. PubMed ID: 37941480
[TBL] [Abstract] [Full Text] [Related]
5. A novel subclonal rearrangement of the STRN3::pdgfrb gene in de novo acute myeloid leukemia with NPM1 mutation and its leukemogenic effects.
Wang Z; Liu T; Liu W; Gao X; Wan L; Qiu S; Song Y; Gu R; Tian Z; Wang M; Wang J; Mi Y; Wei S
Cancer Gene Ther; 2023 Nov; 30(11):1471-1484. PubMed ID: 37550570
[TBL] [Abstract] [Full Text] [Related]
6. Causes of death and treatment-related mortality in newly diagnosed childhood acute lymphoblastic leukemia treatment with Chinese Children's Cancer Group study ALL-2015.
Liu K; Shao J; Cai J; Tang J; Shen S; Xu F; Ren Y; Zhang A; Tian X; Lu X; Hu S; Hu Q; Jiang H; Zhou F; Liang C; Leung AWK; Zhai X; Li C; Fang Y; Wang Z; Wen L; Yang H; Wang N; Jiang H
Ann Hematol; 2023 Dec; 102(12):3431-3444. PubMed ID: 37550503
[TBL] [Abstract] [Full Text] [Related]
7. [Research Progress of m6A Demethylase FTO and Its Inhibitors in Acute Myeloid leukemia --Review].
Fang ZH; Zheng SY; Feng WY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):902-906. PubMed ID: 37356958
[TBL] [Abstract] [Full Text] [Related]
8. Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus.
Moosburner M; Alibegovic L; Hasselmann K; Gaiderov A; Hildebrand J; Philippou-Massier J; Blum H; Fischer L; Dreyling M; Silkenstedt E
Hematol Oncol; 2023 Dec; 41(5):858-868. PubMed ID: 37300279
[TBL] [Abstract] [Full Text] [Related]
9. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
Tan KW; Zhu YY; Qiu QC; Wang M; Shen HJ; Huang SM; Cao HY; Wan CL; Li YY; Dai HP; Xue SL
Ann Hematol; 2023 Sep; 102(9):2397-2402. PubMed ID: 37103615
[TBL] [Abstract] [Full Text] [Related]
10. Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group.
Katodritou E; Kastritis E; Dalampira D; Delimpasi S; Spanoudakis E; Labropoulou V; Ntanasis-Stathopoulos I; Gkioka AI; Giannakoulas N; Kanellias N; Papadopoulou T; Sevastoudi A; Michalis E; Papathanasiou M; Kotsopoulou M; Sioni A; Triantafyllou T; Daiou A; Papadatou M; Kyrtsonis MC; Pouli A; Kostopoulos I; Verrou E; Dimopoulos MA; Terpos E
Am J Hematol; 2023 May; 98(5):730-738. PubMed ID: 36869876
[TBL] [Abstract] [Full Text] [Related]
11. Cardiovascular morbidity following conventional therapy versus allogeneic hematopoietic stem cell transplantation after childhood, adolescent, and young adult leukemia in Finland.
Kero AE; Taskinen M; Volin L; Löyttyniemi E; Itälä-Remes M; Lähteenmäki PM
Int J Cancer; 2023 Jun; 152(11):2292-2302. PubMed ID: 36760204
[TBL] [Abstract] [Full Text] [Related]
12. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion.
Zhang Y; Nguyen L; Lu CM; Wang E; Lauw MIS; Ball S; Dong N; Moscinski L; Chan O; Yun S; Sallman D; Sokol L; Shah B; Knepper T; Lancet J; Komrokji R; Padron E; Kuykendall A; Zhang L
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):e150-e163. PubMed ID: 36624015
[TBL] [Abstract] [Full Text] [Related]
13. Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response-specific osteo-mesenchymal profiles.
Treaba DO; Bonal DM; Chorzalska A; Castillo-Martin M; Oakes A; Pardo M; Petersen M; Schorl C; Hopkins K; Melcher D; Zhao TC; Liang O; So EY; Reagan J; Olszewski AJ; Butera J; Anthony DC; Rintels P; Quesenberry P; Dubielecka PM
Br J Haematol; 2023 Mar; 200(6):740-754. PubMed ID: 36354085
[TBL] [Abstract] [Full Text] [Related]
14. Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling.
Heo SK; Noh EK; Seo HJ; Lee YJ; Koh S; Min YJ; Choi Y; Jo JC
PLoS One; 2022; 17(5):e0265958. PubMed ID: 35503759
[TBL] [Abstract] [Full Text] [Related]
15. Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/pdgfrA axis.
Arribas AJ; Napoli S; Cascione L; Sartori G; Barnabei L; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; Castro de Moura M; Jovic S; Bordone-Pittau R; Di Veroli A; Stathis A; Cruciani G; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
Haematologica; 2022 Nov; 107(11):2685-2697. PubMed ID: 35484662
[TBL] [Abstract] [Full Text] [Related]
16. Myeloid Neoplasm with PCM1-pdgfrb Transcript Responded to Low-Dose Imatinib: One Case Report with Literature Review.
Wang Z; Wan L; Lin D; Li CW; Tian Z; Mi YC
Acta Haematol; 2022; 145(5):560-565. PubMed ID: 35340014
[TBL] [Abstract] [Full Text] [Related]
17. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
[TBL] [Abstract] [Full Text] [Related]
18. Myeloid tumors accompanying systemic mastocytosis, basophilia, and abnormal platelet-derived growth factor receptor β: A case report.
Li Y; Jing Y; Wan H; Liu D
Medicine (Baltimore); 2021 Feb; 100(8):e24707. PubMed ID: 33663081
[TBL] [Abstract] [Full Text] [Related]
19. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.
den Boer ML; Cario G; Moorman AV; Boer JM; de Groot-Kruseman HA; Fiocco M; Escherich G; Imamura T; Yeoh A; Sutton R; Dalla-Pozza L; Kiyokawa N; Schrappe M; Roberts KG; Mullighan CG; Hunger SP; Vora A; Attarbaschi A; Zaliova M; Elitzur S; Cazzaniga G; Biondi A; Loh ML; Pieters R;
Lancet Haematol; 2021 Jan; 8(1):e55-e66. PubMed ID: 33357483
[TBL] [Abstract] [Full Text] [Related]
20. The epigenetic treatment remodel genome-wide histone H4 hyper-acetylation patterns and affect signaling pathways in acute promyelocytic leukemia cells.
Valiulienė G; Vitkevičienė A; Navakauskienė R
Eur J Pharmacol; 2020 Dec; 889():173641. PubMed ID: 33045196
[TBL] [Abstract] [Full Text] [Related]
[Next]
